What You Should Know:
- Evvy, a female-founded startup unlocking precision women’s healthcare through biomarker discovery, announced today the closing of a $14 million Series A funding round led by Left Lane Capital.
- The round also includes General Catalyst, Labcorp Ventures, RH Capital, Ingeborg Investments, G9 Ventures, Virtue, and Amboy Street Ventures.
Funding to Improve the State of Precision Women’s Healthcare
Since its 2021 launch, Evvy has prioritized a data-driven approach to revolutionize women’s health. They utilize exclusive datasets related to female biomarkers, starting with the vaginal microbiome. Their groundbreaking AI-powered vaginal healthcare platform, centered around their microbiome test, combines advanced testing, precise care, and coaching to provide comprehensive care to women and individuals with vaginas. Vaginal discomfort is a top reason for seeking healthcare in the US, but it often leads to misdiagnosis (>50%) and recurrence (>50%). Research has also uncovered significant connections between the vaginal microbiome and infertility, STIs, preterm birth, gynecologic cancers, and more. The capital will be used to expand access to Evvy’s testing and care platform, harness AI to discover new molecular markers for women’s health diagnostics, and validate improved outcomes in fertility, pregnancy, and other areas.
- Since Evvy launched in July 2021, they have achieved many “firsts” in women’s health:
- They launched the first and only metagenomic (mNGS), CLIA/CAP certified, at-home vaginal microbiome test. The Evvy Vaginal Health Test leverages mNGS to screen for all bacteria and fungi that have been isolated from the vaginal and urinary tract in a single swab. Their analytical validation demonstrated industry-leading sensitivity and specificity for hundreds of vaginal microbes.
- They have generated the world’s largest, most comprehensive dataset on the vaginal microbiome — including longitudinal molecular and phenotypic data.
- They launched an integrative, personalized, AI-powered vaginal healthcare platform, and ran an IRB-approved study clinically validating that the platform improves the vaginal microbiome.
- They created Equal Research Day (like Equal Pay Day but for the gender health gap), mobilizing hundreds of doctors, celebrities, patients, and investors. They also assembled an industry-leading advisory board of OB/GYNs and women’s health researchers.
- They built a community of over 200k+ followers across platforms, championing scientifically sound, destigmatized vaginal health education and peer support — finally transforming how we talk about vaginas.
“Evvy’s groundbreaking platform is changing the way we understand and care for the female body,” said Laura Sillman, VP at Left Lane Capital. “We made the strategic decision to invest in Evvy because we deeply believe in their mission and team, and we are confident that their innovative approach will finally unlock a future of women’s healthcare grounded in data. Evvy has already made great strides in closing the gender health gap and we’re excited to be a part of the next phase of their growth journey.”
